Axsome Therapeutics, Inc. (AXSM)

Axsome Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-287.22	-239.24	-187.13	-130.4	-102.9
Depreciation & Amortization	7.96	6.83	4.4	0.08	0.08
Other Amortization	2.64	2.57	1.48	1.08	0.79
Asset Writedown & Restructuring Costs	-	-	-	-	7.16
Stock-Based Compensation	85.22	62.62	37.73	20.8	14.76
Other Operating Activities	29.09	50.52	3.34	-0.1	1.26
Change in Accounts Receivable	-47.18	-57.12	-37.7	-	-
Change in Inventory	0.74	-8.16	-1.33	-	-
Change in Accounts Payable	31.32	2.07	25.46	-0.36	2.56
Change in Other Net Operating Assets	49.02	34.81	37.24	0.68	-2.15
Operating Cash Flow	-128.41	-145.08	-116.51	-108.23	-78.46
Capital Expenditures	-0.27	-0.58	-0.7	-0.31	-0.05
Cash Acquisitions	-	-	-53	-	-
Investing Cash Flow	-0.27	-0.58	-53.7	-0.31	-0.05
Long-Term Debt Issued	-	85	45	-	50
Long-Term Debt Repaid	-0.99	-	-	-	-21.66
Total Debt Repaid	-0.99	-	-	-	-21.66
Net Debt Issued (Repaid)	-0.99	85	45	-	28.34
Issuance of Common Stock	71.46	271.17	250.01	11.84	15.18
Repurchase of Common Stock	-3.95	-1.84	-0.53	-0.18	-
Other Financing Activities	-8.68	-23.32	-9.9	-0.53	-1.1
Financing Cash Flow	57.84	331.01	284.58	11.13	42.41
Net Cash Flow	-70.84	185.35	114.37	-97.4	-36.09
Free Cash Flow	-128.68	-145.66	-117.21	-108.53	-78.5
Free Cash Flow Margin	-33.36%	-53.83%	-234.25%	-	-
Free Cash Flow Per Share	-2.69	-3.21	-2.88	-2.88	-2.11
Cash Interest Paid	19.69	16.73	7.69	4.63	2.1
Levered Free Cash Flow	-28.71	-78.72	-42.36	-59.52	-47.37
Unlevered Free Cash Flow	-27.25	-77.26	-39.26	-57.04	-46.55
Change in Working Capital	33.9	-28.39	23.67	0.32	0.41

Updated Nov 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q